Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer
前列腺癌中 ERG 驱动的管腔命运的机制和脆弱性
基本信息
- 批准号:10572836
- 负责人:
- 金额:$ 17.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:ARNT geneAddressAdenocarcinomaAdvisory CommitteesAmericanAryl Hydrocarbon ReceptorBasal CellBiologyCRISPR screenCancer EtiologyCastrationCellsCessation of lifeChemicalsChromatinClinicalClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCommunicationComputational BiologyDataDependenceDevelopment PlansDimerizationEnvironmentEpithelial CellsEpitheliumFacultyFoundationsGene FusionGeneticGenetically Engineered MouseGoalsGrantHistologyHumanIn VitroIncidenceInvadedKnowledgeLeadershipLigandsMalignant NeoplasmsMalignant neoplasm of prostateMediatingMemorial Sloan-Kettering Cancer CenterMentorsMentorshipModelingMolecularMusOncogenicOncoproteinsOrganoidsOutputPathway interactionsPatientsPopulationPositioning AttributeProliferatingProstateProstaticRNAReceptor SignalingResearchResidual stateResistanceS-Phase FractionSamplingScienceSignal TransductionSolidSpecific qualifier valueTestingTherapeuticTrainingWorkWritingandrogen deprivation therapyanticancer researchcancer cellcancer invasivenesscancer subtypescareercareer developmentclinically relevantcohortgenome wide screengenome-widehormone therapyin vivoinnovationinsightmenmouse modelmultidisciplinarynovelnovel therapeutic interventionoverexpressionpatient subsetsprogenitorprogramsprostate cancer modelresearch and developmentskillssuccesstooltranscription factortranslational cancer researchtumor
项目摘要
Project Summary and Abstract: Prostate cancer (PCa) is the most frequent cancer in American men.
Luminal histology is a hallmark of PCa. Hormone therapy effectively targets luminal cells, but resistance
inevitably occurs. The ERG oncoprotein is overexpressed in half of PCa cases. Prostatic ERG expression in
mice recapitulates invasion with a luminal program seen in human PCa, thus presenting a clinically relevant
model to study PCa. However, the molecular mechanisms by which ERG drives a luminal fate and invasive
PCa remain unclear, insights from which may reveal new treatment paradigms. Project objective: To
elucidate the mechanisms and vulnerabilities of ERG-driven luminal fate and PCa invasion. Preliminary data:
1) pseudo-basal cells (those with a mixture basal/luminal marker profile) rather than luminal cells are the most
proliferative, and invasion-associated population in PCa; 2) a genome-wide CRISPR screen reveals that ERG
stimulates luminal fate by alleviating aryl-hydrocarbon receptor (AHR) signaling, which provides a druggable
vulnerability. Central hypothesis: ERG stimulates a progenitor state, characterized as pseudo-basal cells,
that sustains invasion and luminal output of PCa. The proposed project leverages innovative mouse and
organoid models, genome-wide screen data, and patient samples to test this hypothesis. Specific Aims: 1)
determine the luminal progenitor and oncogenic potential of pseudo-basal cells in ERG-driven PCa; 2) define
how AHR and other screen candidates modulate lineage output as a mechanism and vulnerability of ERG
function; 3) characterize the pseudo-basal state in human PCa. Impact: Success of this work will 1) advance
mechanistic understanding, 2) identify novel vulnerabilities of ERG-driven PCa, the most frequent PCa
subtype, and 3) provide tools and approaches with wide applicability to studying lineage fate choices in cancer.
This work will be performed under the collaborative and resourceful research environment at MSKCC. I have
recently developed CRISPR editing tools for rapid PCa modeling (Proc Natl Acad Sci), which will be critical to
advance the proposed work. My long-term career goal is to establish an independent research team that
focuses on mechanistic understanding of PCa to develop novel therapeutic strategies. I have developed a
detailed career plan to obtain skills in leadership, management, mentoring, grant writing, and scientific
communications. I will work under the mentorship of Dr. Charles Sawyers, a leader in PCa research with a
stellar track record of trainees that went on to faculty positions. In addition, I have assembled an Advisory
Committee that will collaborate with me and offer training on science and career development, including Drs.
Michael Shen (prostate lineage specification), Yu Chen (ERG biology), Gary Perdew (AHR biology), Anuradha
Gopalan (patient sample assessment), and Christina Leslie (computational biology). My research and career
development plan, together with my mentor, advisors and the exceptional academic environment at MSKCC will
provide a solid foundation for my independence in translational prostate cancer research.
前列腺癌(PCa)是美国男性最常见的癌症。
管腔组织学是PCa的标志。激素治疗有效地靶向管腔细胞,但耐药性
不可避免地发生。ERG癌蛋白在一半的PCa病例中过表达。前列腺ERG表达
小鼠重现了在人类前列腺癌中观察到的管腔程序的侵袭,因此呈现出临床相关的
模型研究PCa。然而,ERG驱动管腔命运和侵袭性的分子机制是不确定的。
PCa仍不清楚,从中可以揭示新的治疗模式。项目目标:
阐明ERG驱动的管腔命运和PCa侵袭的机制和脆弱性。初步数据:
1)假基底细胞(具有基底/管腔标记物混合物的细胞)而不是管腔细胞是最常见的。
PCa中增殖和侵袭相关群体; 2)全基因组CRISPR筛选显示,
通过减轻芳香烃受体(AHR)信号传导刺激管腔命运,这提供了一种可药用的
易损性.中心假设:ERG刺激祖细胞状态,其特征为假基底细胞,
维持PCa的侵入和腔输出。拟议的项目利用创新的鼠标和
类器官模型、全基因组筛选数据和患者样本来验证这一假设。具体目标:1)
确定ERG驱动的PCa中假基底细胞的管腔祖细胞和致癌潜力; 2)定义
AHR和其他筛选候选者如何调节作为ERG机制和脆弱性谱系输出
功能; 3)表征人PCa中的伪基础状态。影响:这项工作的成功将1)推进
机制的理解,2)识别ERG驱动的PCa的新漏洞,最常见的PCa
亚型,和3)提供了广泛适用于研究癌症中谱系命运选择的工具和方法。
这项工作将在MSKCC的协作和资源丰富的研究环境下进行。我有
最近开发的用于快速PCa建模的CRISPR编辑工具(Proc Natl Acad Sci),这对于
推进拟议工作。我的长期职业目标是建立一个独立的研究团队,
侧重于PCa的机制理解,以开发新的治疗策略。我开发了一个
详细的职业规划,以获得领导,管理,指导,赠款写作和科学技能
通讯我将在Charles Sawyers博士的指导下工作,他是PCa研究的领导者,
有着出色的培训记录的学员们都能继续担任教职。此外,我还召集了一个顾问团,
委员会将与我合作,并提供科学和职业发展的培训,包括博士。
Michael Shen(前列腺谱系规范)、Yu Chen(ERG生物学)、加里·佩尔杜(AHR生物学)、阿努拉达
Gopalan(患者样本评估)和Christina Leslie(计算生物学)。我的研究和事业
发展计划,连同我的导师,顾问和MSKCC的特殊学术环境将
为我在转化前列腺癌研究中的独立性提供了坚实的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Weiran Feng其他文献
Weiran Feng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 17.3万 - 项目类别:
Research Grant